Reproducibility assessment of tigecycline MIC results by broth microdilution methods using commercially prepared dry-form panels.
We assessed the reproducibility of tigecycline and piperacillin/tazobactam MIC results tested by broth microdilution methods on commercially prepared dry-format panels. Fifteen bacterial isolates were tested 3 times daily for 3 days for a total of 9 replicate results per strain. The within-day and between-days reproducibility was 100% for tigecycline at +/-1 log(2) dilution step and >98% for piperacillin/tazobactam at +/-1 log(2) dilution step. Identical MIC results were observed for 84.4% and 78.7% of tests for same-day replicates for tigecycline and piperacillin/tazobactam, respectively. These results demonstrate the excellent reproducibility of in vitro susceptibility tests for both tigecycline and piperacillin/tazobactam using a commercially prepared dry-form broth microdilution MIC panel.
Rhomberg
Paul R
PR
The Jones Group, JMI Laboratories, North Liberty, IA 52317, USA.
Jones
Ronald N
RN
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000295:instrumentation / Q000379:methods; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology*; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D010878:Piperacillin / Q000494:pharmacology; D000077725:Piperacillin, Tazobactam Drug Combination; D011933:Reagent Kits, Diagnostic; D015203:Reproducibility of Results; D000078304:Tigecycline
D000900:Anti-Bacterial Agents; D011933:Reagent Kits, Diagnostic; D000077725:Piperacillin, Tazobactam Drug Combination; D000078304:Tigecycline; D010397:Penicillanic Acid; D008911:Minocycline; D010878:Piperacillin